Shirley Kalwaney

Dr. Shirley Kalwaney


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2015 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MSMaria Stepanova
Maria Stepanova
LHLinda L. Henry
Linda L. Henry
RGRishi Garg
Rishi Garg
SKShirley Kalwaney
Shirley Kalwaney
SSSammy Saab
Sammy Saab
ZYZobair M. Younossi
Zobair M. Younossi
Non-alcoholic steatohepatitis (NASH) is often seen together with components of metabolic syndrome. The aim of this study was to assess the risk of de novo post-transplant type 2 diabetes (DM) in liver transplant recipients with NASH. All adult patients from the Scientific Registry of Transplant Recipients (2003–2012) transplanted for NASH or cryptogenic cirrhosis (the NASH cohort) without pre-transplant DM were included in this retrospective cross-sectional study. Total 2,916 NASH subjects and 14,268 controls with non-HCV related cirrhosis or hepatocellular carcinoma were included. Patients with NASH were, on average, 6 years older, more likely female and overweight/obese. By 5 years post-transplant, 39.8 % NASH vs. 27.0 % controls developed at least one onset of de novo DM; this was observed starting 6 months post-transplant: 22.9 % vs. 16.7 % (relative risk 1.38). Later in follow-up, the relative risk of de novo DM was also higher in NASH: 1.46 by 3 years, 1.47 by 5 years (all p < 0.0001). After exclusion of DM that resolved after the first year, long-term DM remained higher in the NASH cohort: 7.6 % vs. 4.3 %, p < 0.0001. In multivariate analysis, after adjustment for confounders including the use of immunosuppressants, having NASH was independently associated with development of de novo post-transplant DM: adjusted hazard ratio (95 % CI) = 1.29 (1.18–1.42), p < 0.0001. Liver transplant recipients with NASH have a higher risk of de novo post-transplant DM. This suggests the presence of an underlying metabolic disorder beyond fatty liver that may be causative for both NASH and type 2 diabetes.

1 May 2013 in Gastroenterology
Verified
Journal Article
Open access
AMAlita Mishra
Alita Mishra
MSMaria Stepanova
Maria Stepanova
SKShirley Kalwaney
Shirley Kalwaney
CVChapy Venkatesan
Chapy Venkatesan
MAMariam Afendy
Mariam Afendy
OTOthers
Others

1 April 2026 in Pediatric Clinics of North America
Verified
Journal Article
Closed access
SKShirley Kalwaney
Shirley Kalwaney
LPLisa Patel
Lisa Patel